ClinicalTrials.gg

Program

AK146D1

A development code. Also written as “AK146D1 for injection”.

Its studies are mostly in Breast Neoplasms · Carcinoma, Transitional Cell, led by Akeso.

Furthest: phase 2, since May 9, 20264 company-led studies, 4 open or runningNext primary completion: Sep 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Akeso44 open or runningphase 2since May 9, 2026Mar 16, 2025Sep 1, 2027phase 2 · NCT07591090

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 16, 2025First study: phase 1 study in Advanced Solid TumorsFirst studyNCT06929663 · 166 planned · Australia
  2. Jun 18, 2025Phase 1 study in Advanced Solid TumorsNCT07067567 · 200 planned · China
  3. May 9, 2026Phase 2 study in Advanced Breast CancerPhase 2 reachedNCT07591090 · 200 planned · China
  4. Jun 4, 2026Phase 2 study in Carcinoma, Transitional CellNCT07636772 · 132 planned · China

Ahead

  1. Nov 5, 2026Primary completion: phase 1 study in Advanced Solid TumorsNCT07067567
  2. Sep 1, 2027Primary completion: phase 2 study in Advanced Breast CancerNCT07591090
  3. Jun 30, 2028Primary completion: phase 1 study in Advanced Solid TumorsNCT06929663
  4. Aug 24, 2028Primary completion: phase 2 study in Carcinoma, Transitional CellNCT07636772

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07636772Carcinoma, Transitional Cell · China2Not yet recruitingAug 24, 2028132
NCT07591090Advanced Breast Cancer · China2RecruitingSep 1, 2027200
NCT07067567Advanced Solid Tumors · China1RecruitingNov 5, 2026200
NCT06929663Advanced Solid Tumors · Australia1RecruitingJun 30, 2028166

How it is read

Names in the registry

  • “AK146D1 for injection”, 4 entries

Codes read as this program: AK146D1.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.